Pay in 4 interest-free payments of $6.49 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Lynparza (olaparib) Disease area(s): Oncology Manufacturer(s): AstraZeneca/Merck 2024 Sales (USD): $4.98 billion Why it sold so well: AstraZenecas Lynparza delivered a strong sales performance in 2024, with product revenues reaching $3.67 billion, marking a 22% increase at constant exchange rates compared to the previous year
Treatment for rosacea At McKeown Medical, we offer clinically proven treatment options to tackle rosacea and improve the appearance of your skin
L-carnitine is often marketed as a fat-burning supplement because it helps metabolise fatty acids
Despite providing considerable weight loss, only between 0.5 and 1% of eligible patients undergo bariatric surgery [6]
Data was de-identified before analysis
US$ 29.70
US$ 21.39
US$ 22.74
US$ 22.64
US$ 24.61
US$ 26.31
US$ 21.91
US$ 28.41
US$ 28.16
US$ 22.92
US$ 28.15
US$ 27.70
